Anticonvulsant medication use in veterans with posttraumatic stress disorder

Journal of Clinical Psychiatry

Volumn 78, Issue 5, 2017, Pages e545-e552

  Shiner, Brian ^a,b   Westgate, Christine Leonard ^a   Bernardy, Nancy C ^b,c   Schnurr, Paula P ^b,c   Watts, Bradley V ^b,d  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NATIONAL CENTER FOR PTSD   (United States)

^d VA National Center for Patient Safety   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LEVETIRACETAM; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; ALCOHOLISM; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG INDICATION; ELECTRONIC MEDICAL RECORD; FEMALE; GOVERNMENT; HEADACHE; HUMAN; IMPULSE CONTROL DISORDER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PAIN; PHARMACY; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SCHIZOAFFECTIVE PSYCHOSIS; SEIZURE; TREND STUDY; VETERAN; AGED; COMBAT DISORDERS; COMORBIDITY; DRUG UTILIZATION; MENTAL DISORDERS; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

ADULT; AGED; ANTICONVULSANTS; COMBAT DISORDERS; COMORBIDITY; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; VETERANS;

EID: 85019612092     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16m11031     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
2. Pietrzak RH, Goldstein RB, Southwick SM, et al. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25(3):456-465. PubMed doi:10.1016/j.janxdis.2010.11.010
3. Magruder KM, Frueh BC, Knapp RG, et al. Prevalence of posttraumatic stress disorder in veterans affairs primary care clinics. Gen Hosp Psychiatry. 2005;27(3):169-179. PubMed doi:10.1016/j.genhospps ych. 20 0 4.11.0 01
4. Shiner B, Drake RE, Watts BV, et al. Access to VA services for returning veterans with PTSD. Mil Med. 2012;177(7):814-822. PubMed doi:10.7205/MILMED-D-12-00009
5. Jonas DE, Cusack K, Forneris CA, et al. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder. Rockville, MD: Agency for Healthcare Research and Quality; 2013. doi:10.1037/e553842013-001
6. Watts BV, Schnurr PP, Mayo L, et al. Metaanalysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74(6):e541-e550. PubMed d o i:10. 4 0 8 8/J CP.12r 0 8225
7. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283(14): 1837-1844. PubMed doi:10.1001/jama.283.14.1837
8. Connor KM, Sutherland SM, Tupler LA, et al. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry. 1999;175:17-22. PubMed doi:10.1192/bjp.175.1.17
9. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006;63(10):1158-1165. PubMed doi:10.1001/archpsyc.63.10.1158
10. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158(12):1982-1988. PubMed doi:10.1176/appi.ajp.158.12.1982
11. Lado FA, Moshé SL. How do seizures stop? Epilepsia. 2008;49(10):1651-1664. PubMed doi:10.1111/j.1528-1167.2008.01669.x
12. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10(7):685-692. PubMed doi:10.1038/nm1074
13. Friedman MJ. Neurobiological sensitization models of post-traumatic stress disorder: their possible relevance to multiple chemical sensitivity syndrome. Toxicol Ind Health. 1994;10(4-5):449-462. PubMed
14. Post RM, Weiss SRB, Smith MA. Sensitization and kindling: implications for the evolving neural substrates of post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress. Philadelphia, PA: Lippincott-Raven Publishers; 1995:203-224.
15. Post RM, Weiss SR, Li H, et al. Sensitization components of post-traumatic stress disorder: implications for therapeutics. Semin Clin Neuropsychiatry. 1999;4(4):282-294. PubMed
16. Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007;27(1):85-88. PubMed doi:10.1097/JCP.0b013e31802e5115
17. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45(9):1226-1229. PubMed doi:10.1016/S0 0 0 6-3223(99)0 0 011-6
18. Baniasadi M, Hosseini G, Fayyazi Bordbar MR, et al. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract. 2014;20(6):419-427. PubMed doi:10.1097/01.pra.0000456590.12998.41
19. Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008;28(1):84-88. PubMed doi:10.1097/JCP.0b013e318160f83b
20. Hamner MB, Faldowski RA, Robert S, et al. A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry. 2009;21(2):89-94. PubMed
21. Yeh MS, Mari JJ, Costa MC, et al. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011;17(5):305-310. PubMed doi:10.1111/j.1755-5949.2010.00188.x
22. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(2):201-206. PubMed doi:10.4088/JCP.v68n0204
23. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combatrelated posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27(6):677-681. PubMed doi:10.1097/jcp.0b013e31815a43ee
24. Akuchekian S, Amanat SA. A comparison of topiramate and placebo in the treatment of posttraumatic stress disorder: a randomized, double-blind study. J Res Med Sci. 2004;5(5):240-244.
25. Bisson J, Ehlers A. Post-traumatic stress disorder: management. Clinical guideline [CG26]. National Institute for Clinical Excellence website. http://www.nice.org.uk/nicemedia/pdf/CG026NICEguideline.pdf. 2005.
26. Foa EB, Keane TM, Friedman MJ, et al, eds. Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies. Second Edition. New York, NY: The Guilford Press; 2010.
27. Friedman MJ, Lowry P, Ruzek J. VA/DoD clinical practice guidelines for the management of post-traumatic stress. United States Departments of Veterans Affairs and Defense website. http://www.healthquality. va.gov/PTSD-Full-2010c.pdf. 2010.
28. Benedek DM, Friedman MJ, Zatzick D, et al. Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. http://psychiatryonline.org/pb/assets/raw/sitewide/practice-guidelines/guidelines/acutestressdisorderptsd-watch. pdf. 2009. Accessed April 4, 2017.
29. Jain S, Greenbaum MA, Rosen C. Concordance between psychotropic prescribing for veterans with PTSD and clinical practice guidelines. Psychiatr Serv. 2012;63(2):154-160. PubMed doi:10.1176/appi.ps.201100199
30. Marshall JG, Sollenberger J, EasterbyGannett S, et al. The value of library and information services in patient care: results of a multisite study. J Med Libr Assoc. 2013;101(1):38-46. PubMed doi:10.3163/1536-5050.101.1.007
31. Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481-1488. PubMed doi:10.1111/acer.12411
32. Batki SL, Pennington DL, Lasher B, et al. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 2014;38(8):2169-2177. PubMed doi:10.1111/acer.12496
33. Prabhavalkar KS, Poovanpallil NB, Bhatt LK. Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Front Pharmacol. 2015;6:242. PubMed doi:10.3389/fphar.2015.00242
34. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatmentresistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry. 2008;10(3):187-190. PubMed doi:10.4088/PCC.v10n0302
35. Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry. 2011;72(10):1405-1412. PubMed doi:10.4088/JCP.09m05355gre
36. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13(3):141-146. PubMed doi:10.3109/10401230109148960
37. Wang HR, Woo YS, Bahk WM. Anticonvulsants to treat post-traumatic stress disorder. Hum Psychopharmacol. 2014;29(5):427-433. PubMed doi:10.1002/hup